Water-soluble chitosan-based antisense oligodeoxynucleotide of interleukin-5 for treatment of allergic rhinitis

Biomaterials

Volumn 28, Issue 22, 2007, Pages 3360-3368

  Kim, Sung Tae ^a   Kim, Chong Kook ^a  

^a Seoul National University   (South Korea)

Author keywords

Allergic rhinitis; Antisense oligodeoxynucleotide; Interleukin 5; Water soluble chitosan

Indexed keywords

ALLERGIC RHINITIS; ENZYMATIC DEGRADATION; INTERLEUKIN (IL) 5; TRANSFECTION EFFICIENCY;

ALLERGIES; BIOCOMPATIBILITY; CHITIN; FLOW CYTOMETRY; OLIGONUCLEOTIDES; ZETA POTENTIAL;

GLYCOPROTEINS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; BIOMATERIAL; CHITOSAN; IMMUNOGLOBULIN E; INTERLEUKIN 5; INTERLEUKIN 5 ANTISENSE OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANIMAL CELL; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; ENZYME DEGRADATION; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; CATIONS; CHITOSAN; FEMALE; GENE THERAPY; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-5; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES, ANTISENSE; RHINITIS; SOLUBILITY; TH2 CELLS; WATER;

MURINAE;

EID: 34247871390     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.03.029     Document Type: Article

References (43)

1. Scavuzzo M.C., Rocchi V., Fattori B., Ambrogi F., Carpi A., Ruffoli R., et al. Cytokine secretion in nasal mucus of normal subjects and patients with allergic rhinitis. Biomed Pharmacother 57 (2003) 366-371
2. Brett E., and Stanaland M.D. Once-daily budesonide aqueous nasal spray for allergic rhinitis: a review. Clin Ther 26 4 (2004) 473-479
3. Ratnet P.H., Wingertzahn M.A., Bavel J.H., Hamperl F., Darken P.F., and Shah T. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 118 5 (2006) 1142-1148
4. Romagnani S. Immunologic influences on allergy and the Th1/Th2 balance. J Allergy Clin Immunol 113 3 (2004) 395-400
5. Leckie M.J., Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
6. Foster P.S., Hogan S.P., Yang M., Mattes J., Young I.G., Matthaei K.I., et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med 8 4 (2002) 162-167
7. Ohashi Y., Nakai Y., Tanaka A., Kakinoki Y., Masamoto T., Kato A., et al. Allergen-induced mRNA expression of interleukin-5, but not of interleukin-4 and interferon-r, in peripheral blood mononuclear cells obtained before the pollen season predicts the clinical efficacy of immunotherapy for seasonal allergic rhinitis. Scan J Immunol 51 (2000) 202-208
8. Kita H., Jorgensen R.K., Reed C.E., Dunnette S.L., Swanson M.C., Bartemes K.R., et al. Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected. J Allergy Clin Immunol 106 3 (2000) 521-529
9. Shi H.Z., Xiao C.Q., Zhong D., Qin S.M., Liu Y., Liang G.R., et al. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med 157 1 (1998) 204-209
10. Kay A.B., Phipps S., and Robinson D.S. A role for eosinophils in airway remodeling in asthma. Trends Immunol 35 9 (2004) 477-482
11. Akhtar S., Hughes M.D., Khan A., Bibby M., Hussain M., Nawaz Q., et al. The delivery of antisense therapeutics. Adv Drug Del Rev 44 (2000) 3-21
12. Schmidt-Wolf G.D., and Schmidt-Wolf I.G.H. Non-viral and hybrid vectors in human gene therapy: an update. Trends Mol Med 9 2 (2003) 67-72
13. Merdan T., Kopečk J., and Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Del Rev 54 (2002) 715-758
14. Kim T.H., Park I.K., Nah J.W., Choi Y.J., and Cho C.S. Galactosylated chitosan/DNA nanoparticles prepared using water soluble chitosan as a gene carrier. Biomaterials 25 (2004) 3783-3792
15. Lee M., Nah J., Kwon Y., Koh J.J., Ko K.S., and Kim S.W. Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm Res 18 4 (2001) 427-431
16. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., and Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm 57 (2004) 1-8
17. Guliyeva U., Oner F., Ozsoy S., and Haziroglu R. Chitosan microparticles containing plasmid DNA as potential oral gene delivery system. Eur J Pharm Biopharm 62 (2006) 17-25
18. MacLaughlin F.C., Mumper R.J., Wang J., Tagliaferri J.M., Gill I., Hinchcliffe M., et al. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 56 (1998) 259-272
19. Erbacher P., Zou S., Bettinger T., Steffan A.M., and Remy J.S. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res 15 9 (1998) 1332-1339
20. Seong J.H., Lee M.K., Kim S.T., Jin S.E., and Kim C.K. Polyethylenimine-based antisense oligonucleotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation. J Gene Med 8 (2006) 314-323
21. Rhee C., Libet L., Chisholm D., Takabayashi K., Baird S., Bigby T.D., et al. Allergen-independent immunostimulatory sequence oligodeoxy-nucleotide therapy attenuates experimental allergic rhinitis. Immunology 113 (2004) 106-113
22. Fiset P.O., Soussi-Gounni A., Christodoulopoulos P., Tulic M., Sobol S.E., Frenkiel S., et al. Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4. J Allergy Clin Immunol 111 3 (2003) 580-587
23. Philippe G., Doris L., Andreas L., Heinz S., Heribert S., Thibaut V.Z., et al. Nasal IL-5 levels determines the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118 5 (2006) 1133-1141
24. Wilson D.R., Nouri-Aria K.T., Walker S.M., Pajno G.B., O'Brien F., Jacobson M.R., et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 107 6 (2001) 971-975
25. Denburg J.A. Hemopoietic mechanisms in allergy. Rev Française D'allergologie D'Immunol Clin 44 (2004) 9-13
26. Kakinoki Y., Ohashi Y., Nakai Y., Wahio Y., Nasako Y., Tanaka A., et al. Allergic induced mRNA expression of interleukin-5, but not of interleukin-4 and interferon-γ, in peripheral blood mononuclear cells obtained before the pollen season predicts the clinical efficacy of immunotherapy for seasonal allergic rhinitis. Scand J Immunol 51 (2000) 202-208
27. Kurreck J. Antisense technologies. Eur J Biochem 270 (2003) 1628-1644
28. Dallas A., and Vlassov A.V. RNAi: a novel antisense technology and its therapeutic potential. Med Sci Monit 12 4 (2006) RA67-RA74
29. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., and Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm 57 (2004) 1-8
30. Bozkir A., and Saka O.M. Chitosan-DNA nanoparticles: effect on DNA integrity, bacterial transformation and transfection efficiency. J Drug Targets 12 5 (2004) 281-288
31. Lavertu M., Methot S., Tran-Khanh N., and Buschmann M. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 27 (2006) 4815-4824
32. Boonsongrit Y., Mitrevej A., and Muller B.W. Chitosan drug binding by ionic interaction. Eur J Pharm Biopharm 62 (2006) 267-274
33. Baudner B.C., Giuliani M.M., Verhoef J.C., Rappuoli R., Junginger H.E., and Giudice G.D. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administrated vaccines. Vaccine 21 (2003) 3837-3844
34. Prego C., Garcia M., Torres D., and Alonso M.J. Transmucosal macromolecular drug delivery. J Control Release 101 (2005) 151-162
35. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., and Davis S.S. Chitosan as a novel nasal delivery system for vaccine. Adv Drug Deliv Rev 51 (2001) 81-96
36. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., and Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL response in BALB/c mice. Vaccine 21 (2003) 1478-1485
37. Ishii T., Okahata Y., and Sato T. Mechanism of cell transfection with plasmid/chitosan complexes. Biochem Biophys Acta 1514 (2001) 51-64
38. Lamblin C., Bolard F., Gosset P., Tsicopoulos A., Perez T., Darras J., et al. Bronchial interleukin-5 and eotaxin expression in nasal polyposis. Am J Respir Crit Care Med 163 (2001) 1226-1232
39. KleinJan A., Willart M., Rhijt L.S., Braunstahl G., Leman K., Jung S., et al. An essential role for dendritic cells in human and experimental allergic rhinitis. J Allergy Clin Immunol 118 5 (2006) 1117-1125
40. Powe D.G., and Jones N.S. Local mucosal immunoglobulin E production: does allergy exist in non-allergic rhinitis?. Clin Exp Allergy 36 (2006) 1367-1372
41. Leckie M.J., Brinke A., Khan J., Diamant Z., O'Conner B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
42. Menzies-Gow A., Flood-Page P., Sehmi R., Burman J., Hamid Q., Robinson D.S., et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111 4 (2003) 714-719
43. Klion A.D., Law M.A., Noel P.N., Kim Y., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 15 (2004) 2939-2941